


PHARMACEUTICAL 2021

Skye Bioscience Inc. Rank 391 of 409





Skye Bioscience Inc. Rank 391 of 409

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 155% points. The greatest weakness of Skye Bioscience Inc. is the variable Net Income, reducing the Economic Capital Ratio by 587% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,069%, being 714% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	787
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.6
Other Liabilities	1,434
Other Net Income	-270
Property and Equipment	7.3
Research and Development	1,944
Revenues	0
Selling, General and Administrative Expense	4,345

Output Variable	Value in 1000 USD
Assets	2,672
Liabilities	2,221
Expenses	6,291
Stockholders Equity	451
Net Income	-6,561
Comprehensive Net Income	-6,561
Economic Capital Ratio	-1,069%

